Hey Flip, haven't you been saying this, with respect to crossover
"While the administration of DCVs after maximal surgical resection is typically advocated due to the idea that decreased tumor burden leads to a decrease in tumor-associated immune suppression and stronger cytotoxic immune response, the timing of DCVs in conjunction with or after adjuvant chemoradiation is less clear [218]"